DrugPatentWatch Database PreviewSee Plans and Pricing
« Back to Dashboard
Amylamine is an investigational drug.
There have been 18 clinical trials for Amylamine. The most recent clinical trial was a Phase 3 trial, which was initiated on April 18th 2019.
The most common disease conditions in clinical trials are Depressive Disorder, Depression, and Depressive Disorder, Major. The leading clinical trial sponsors are CoMentis, Yale University, and Targacept Inc.
There are two US patents protecting this investigational drug and twenty-seven international patents.
Recent Clinical Trials for Amylamine
|Pilot Study of Mecamylamine for Autonomic Dysreflexia Prophylaxis||Wayne State University||Phase 4|
|Exploratory Study to Assess the Efficacy and Safety of TC-5214 in the Treatment of Subjects With Palmar Hyperhidrosis||Atacama Therapeutics||Phase 2|
|The Nicotinic Cholinergic System and Cognitive Aging||Vanderbilt University Medical Center||Phase 1|
Top disease conditions for Amylamine
Top clinical trial sponsors for Amylamine
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|Amylamine||Start Trial||Process for protecting bearings in steel mills and other metal processing mills||Amoco Corporation (Chicago, IL)||Start Trial|
|Amylamine||Start Trial||Polymers derived from unsaturated polyesters by addition of compounds with an amine function and their use as additives modifying the properties of petroleum middle distillates when cold||Institut Francais du Petrole (Rueil-Malmaison, FR) Elf France (Corbevoie, FR)||Start Trial|
|Amylamine||Start Trial||Preparation of organometallic amide compositions||Lithium Corporation of America (Gastonia, NC)||Start Trial|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|